Notably, other studies have recently reported that serum TFF3 is increased in patients with lung cancer, endometrial cancer, and prostate cancer, and that TFF3 is expressed in the tissue of these cancers[24,26,27]. Here, TFF3 is linked to prostate carcinoma.